Palisade Bio PALI Stock
Palisade Bio Price Chart
Palisade Bio PALI Financial and Trading Overview
| Palisade Bio stock price | 2.07 USD |
| Previous Close | 2.1 USD |
| Open | 2.09 USD |
| Bid | 2.01 USD x 100 |
| Ask | 2.59 USD x 200 |
| Day's Range | 2 - 2.1 USD |
| 52 Week Range | 0.53 - 2.86 USD |
| Volume | 1.61M USD |
| Avg. Volume | 2.99M USD |
| Market Cap | 350.28M USD |
| Beta (5Y Monthly) | 1.538 |
| PE Ratio (TTM) | 3.2419355 |
| EPS (TTM) | 0.67 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.22 USD |
PALI Valuation Measures
| Enterprise Value | 225.11M USD |
| Trailing P/E | 3.2419355 |
| Forward P/E | -7.178571 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 700.5676 |
| Price/Book (mrq) | 2.8673325 |
| Enterprise Value/Revenue | 450.228 |
| Enterprise Value/EBITDA | -6.369 |
Trading Information
Palisade Bio Stock Price History
| Beta (5Y Monthly) | 1.538 |
| 52-Week Change | 195.58% |
| S&P500 52-Week Change | 18.35% |
| 52 Week High | 2.86 USD |
| 52 Week Low | 0.53 USD |
| 50-Day Moving Average | 1.99 USD |
| 200-Day Moving Average | 1.94 USD |
PALI Share Statistics
| Avg. Volume (3 month) | 2.99M USD |
| Avg. Daily Volume (10-Days) | 1.77M USD |
| Shares Outstanding | 174.27M |
| Float | 138.85M |
| Short Ratio | 10.91 |
| % Held by Insiders | 1.68% |
| % Held by Institutions | 101.49% |
| Shares Short | 33.7M |
| Short % of Float | 19.42% |
| Short % of Shares Outstanding | 19.38% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -2339.60% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -32.97% |
| Return on Equity (ttm) | -51.36% |
Income Statement
| Revenue (ttm) | 500K USD |
| Revenue Per Share (ttm) | 0.003 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 500K USD |
| EBITDA | -35346500 USD |
| Net Income Avi to Common (ttm) | -31941000 USD |
| Diluted EPS (ttm) | 0.62 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 125.17M USD |
| Total Cash Per Share (mrq) | 0.72 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 24.258 |
| Book Value Per Share (mrq) | 0.701 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -18190000 USD |
| Levered Free Cash Flow (ttm) | -8654125 USD |
Profile of Palisade Bio
| Country | United States |
| State | CO |
| City | Denver |
| Address | 4600 South Syracuse Street |
| ZIP | 80237 |
| Phone | 858 704 4900 |
| Website | https://www.palisadebio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 14 |
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Q&A For Palisade Bio Stock
What is a current PALI stock price?
Palisade Bio PALI stock price today per share is 2.07 USD.
How to purchase Palisade Bio stock?
You can buy PALI shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Palisade Bio?
The stock symbol or ticker of Palisade Bio is PALI.
Which industry does the Palisade Bio company belong to?
The Palisade Bio industry is Biotechnology.
How many shares does Palisade Bio have in circulation?
The max supply of Palisade Bio shares is 174.27M.
What is Palisade Bio Price to Earnings Ratio (PE Ratio)?
Palisade Bio PE Ratio is 3.08955220 now.
What was Palisade Bio earnings per share over the trailing 12 months (TTM)?
Palisade Bio EPS is 0.67 USD over the trailing 12 months.
Which sector does the Palisade Bio company belong to?
The Palisade Bio sector is Healthcare.
Palisade Bio PALI included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26151.3 USD — |
+0.66
|
6.62B USD — | 26034.35 USD — | 26225.83 USD — | — - | 6.62B USD — |
|
US Tech Health Care
IXHC
US
|
1378.65 USD — |
+1.27
|
— — | 1366.6 USD — | 1381.83 USD — | — - | — — |
- {{ link.label }} {{link}}
